Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Nab-Paclitaxel Shows Promise in Advanced Lung Cancer

July 3rd 2012

The administration of nab-paclitaxel plus carboplatin results in a significantly higher ORR than conventional solvent-based paclitaxel with carboplatin in previously untreated patients with advanced NSCLC.

LDCT Scans Gain Support Amid Lingering Concerns

June 28th 2012

Three medical societies have joined in endorsing low-dose computed tomography screening for patients at high risk of developing lung cancer.

Dr. Kirkman on the Combination of PX-866 and Docetaxel

June 27th 2012

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Perez-Soler on Erlotinib-Induced Skin Rash and Survival

June 27th 2012

Dr. Roman Perez-Soler, from the Montefiore Medical Center, on the Correlation Between Erlotinib-Induced Skin Rash and Overall Survival

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Sandler Discusses the Tivantinib Mechanism of Action

June 25th 2012

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of Inhibitors

June 25th 2012

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.

Older Lung Cancer Patients Do Not Benefit From Bevacizumab Added to Standard Treatment

June 24th 2012

The addition of bevacizumab to first-line carboplatin-paclitaxel did not prolong survival in Medicare recipients with advanced non–small cell lung cancer.

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

June 22nd 2012

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Dr. Gandara on TS Expression in ALK-Positive NSCLC

June 19th 2012

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Kris Discusses ASCO 2012 Lung Cancer Information

June 18th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Afatinib Prolongs PFS in Lung Cancer Trial

June 4th 2012

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

June 2nd 2012

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Thalidomide Added to Chemoradiotherapy Shows No Benefit as Lung Cancer Treatment

April 25th 2012

The addition of thalidomide to chemoradiotherapy provides no survival benefit and increases toxicity in patients with unresectable stage III non-small cell lung cancer.

Dr. Gore on Toxicity in Elderly Lung Cancer Patients

April 18th 2012

Dr. Elizabeth Gore, from the Medical College of Wisconsin, on Toxicity in Elderly Lung Cancer Patients

Going Beyond the Label: Targeted Therapies Present New Questions in Clinical Use

April 18th 2012

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

Many Patients Continue to Smoke After Cancer Diagnosis

April 11th 2012

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

NEXT PAGE
PREVIOUS PAGE